COGT Stock Discussion
Cogent Biosciences, Inc. Description
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Cogent's most advanced program, PLX9486, is a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent is headquartered in Cambridge, MA.
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Disease Gastrointestinal Enzymes Protein Kinase Inhibitor Tyrosine Kinase Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Imatinib Gastrointestinal Stromal Tumors
Recent Comments
- TraderMike on Bollinger Band Squeeze
- TraderMike on Bollinger Band Squeeze
- OpenCat584 on Bollinger Band Squeeze
- Dr_Duru on Expansion Breakout
- TraderMike on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
From the Blog
Featured Articles